The FDA has approved SpringWorks Therapeutics’s mirdametinib (Gomekli) for adult and paediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback